Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings

Maham Fatima

Sat, February 14, 2026 at 3:28 PM GMT+9 2 min read

In this article:

PFE

+0.40%

Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its Market Perform rating and $30 price target for Pfizer following a Q4 2o25 earnings report that exceeded expectations with $17.6 billion in revenue and $0.66 EPS. Despite strong financial results and a raised 2025 EPS guidance of $3.22, the firm remains cautious as Pfizer navigates a transitional period.

Bernstein particularly highlighted that the company made some big bets, positioning 2026 as a critical year of waiting to determine if these strategic choices will ultimately yield the intended results. Throughout 2026, the market will closely monitor Pfizer’s clinical development progress, specifically focusing on key decisions regarding dosing, frequency, and trial design.

While Pfizer continues to outperform consensus estimates and manage declining COVID-related sales, its long-term valuation remains tied to how these significant investments and clinical milestones play out over the coming year.

In other news, the FDA granted Priority Review to Pfizer’s sBLA for HYMPAVZI (marstacimab), seeking to expand its indication to include hemophilia A or B patients aged 6 and older with inhibitors, as well as pediatric patients aged 6 to 11 without inhibitors. Currently approved in the US for patients 12 and older without inhibitors, HYMPAVZI would become the first non-factor prophylactic treatment for children aged 6 to 11 with hemophilia B if approved.

Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now**.**

Disclosure: None. This article is originally published at Insider Monkey.

Terms and Privacy Policy

Privacy Dashboard

More Info